SWX:MOLN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Molecular Partners's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MOLN is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MOLN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.


Market Performance


7 Day Return

-0.5%

MOLN

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

-2.3%

MOLN

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: MOLN underperformed the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: MOLN underperformed the Swiss Market which returned -0.4% over the past year.


Shareholder returns

MOLNIndustryMarket
7 Day-0.5%3.6%0.4%
30 Day-3.7%1.6%2.7%
90 Day28.5%3.7%6.1%
1 Year-2.3%-2.3%2.6%1.3%3.1%-0.4%
3 Year-16.8%-16.8%4.3%1.9%19.8%4.7%
5 Year-34.4%-34.4%70.1%64.3%52.0%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Molecular Partners's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Molecular Partners undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MOLN (CHF21) is trading below our estimate of fair value (CHF107.16)

Significantly Below Fair Value: MOLN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MOLN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: MOLN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MOLN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MOLN is overvalued based on its PB Ratio (14.8x) compared to the CH Biotechs industry average (3x).


Next Steps

Future Growth

How is Molecular Partners forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

49.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOLN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOLN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOLN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOLN's revenue (27.1% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: MOLN's revenue (27.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MOLN's Return on Equity is forecast to be low in 3 years time (13.8%).


Next Steps

Past Performance

How has Molecular Partners performed over the past 5 years?

-35.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MOLN is currently unprofitable.

Growing Profit Margin: MOLN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MOLN is unprofitable, and losses have increased over the past 5 years at a rate of 35.5% per year.

Accelerating Growth: Unable to compare MOLN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: MOLN has a negative Return on Equity (-155.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is Molecular Partners's financial position?


Financial Position Analysis

Short Term Liabilities: MOLN's short term assets (CHF68.5M) exceed its short term liabilities (CHF29.5M).

Long Term Liabilities: MOLN's short term assets (CHF68.5M) exceed its long term liabilities (CHF12.9M).


Debt to Equity History and Analysis

Debt Level: MOLN is debt free.

Reducing Debt: MOLN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOLN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MOLN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Molecular Partners's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MOLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MOLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MOLN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MOLN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MOLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Patrick Amstutz (45 yo)

4.17yrs

Tenure

CHF930,000

Compensation

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting C...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD1.05M) is about average for companies of similar size in the Swiss market ($USD1.17M).

Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Patrick Amstutz
Co-Founder4.17yrsCHF930.00k2.41%
CHF 14.7m
Michael Stumpp
Co-Founder17yrsno data2.61%
CHF 16.0m
Andreas Emmenegger
CFO & Member of Management Board13.75yrsno data0.82%
CHF 5.0m
Nicolas Leupin
Chief Medical Officer & Member of Management Board1.33yrsno datano data
Hans Binz
Vice President of Technologyno datano datano data
Seth Lewis
Senior Vice President of Investor Relationsno datano datano data
Julien Gander
General Counsel4.5yrsno datano data
Thomas Schwerzmann
Vice President of Human Resources1.75yrsno datano data
Alexander Zürcher
Senior Vice President of Development1.75yrsno datano data
Daniel Steiner
Senior Vice President of Oncology Research1.75yrsno datano data
Thomas Schneckenburger
Vice President of Financeno datano datano data
Pamela Trail
Strategic Consultant1.5yrsno datano data

1.8yrs

Average Tenure

48yo

Average Age

Experienced Management: MOLN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Patrick Amstutz
Co-Founder4.17yrsCHF930.00k2.41%
CHF 14.7m
Steven Holtzman
Non Executive Director7yrsCHF109.00k0.013%
CHF 81.5k
William A. Burns
Chairman of the Board2.75yrsCHF327.00kno data
Gwen Fyfe
Director3.67yrsCHF109.00kno data
Vito Palombella
Director0.75yrno datano data
Michael Vasconcelles
Director0.75yrno datano data
Sandip Kapadia
Director0.75yrno datano data

2.8yrs

Average Tenure

57yo

Average Age

Experienced Board: MOLN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.9%.


Top Shareholders

Company Information

Molecular Partners AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Molecular Partners AG
  • Ticker: MOLN
  • Exchange: SWX
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF612.087m
  • Shares outstanding: 29.15m
  • Website: https://www.molecularpartners.com

Number of Employees


Location

  • Molecular Partners AG
  • Wagistrasse 14
  • Schlieren
  • Zurich
  • 8952
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOLNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFNov 2014
0QXXLSE (London Stock Exchange)YesRegistered SharesGBCHFNov 2014
6MLDB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2014
MLLC.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDNov 2014

Biography

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-r...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 03:13
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.